CEO Per Norlén comments on the Nobel Prize in Physiology or Medicine 2018
Tasuku Honjo & James Allison share the 2018 Nobel Prize in Physiology or Medicin. Photo: Wikimedia CommonsOn Monday October 1st the Nobe ...
New preclinical data support good tolerability properties for the 4-1BB antibody ATOR-1017
Lund, Sweden, September 28, 2018 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmac ...
Alligator Bioscience presents at the 20th Annual Rodman & Renshaw Global Investment Conference
Lund, Sweden, August 30 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceuticals ...
Alligator Bioscience submits application to start clinical phase I study in cancer patients with ATOR-1015, a unique CTLA-4 and OX40 binding antibody
Lund, Sweden, July 19, 2018 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceutic ...
Alligator Bioscience AB Interim Report January-June 2018
Positive data for our preclinical projects Significant events April-June• The ADC-1013 clinical phase I study performed by Janssen is ongoin ...
Frontier – A Magazine about Alligator Bioscience and Immuno-oncology
To read the whole magazine, open the PDF-file at the bottom of this email.
Alligator Bioscience’s ATOR-1017 strongly activates both T cells and NK cells, important for the effective eradication of tumor cells
– Further preclinical findings support a best-in-class profile – Oral presentation at World Preclinical Congress, ...
Alligator Bioscience Capital Markets Day today on May, 29
Meet the future of antibody-based immuno-oncology drugs Lund, Sweden, May 29, 2018 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a ...
Invitation to Alligator Bioscience Capital Markets Day in Stockholm on May 29, 2018
Meet the future of antibody-based immuno-oncology drugs Lund, Sweden, May 16, 2018 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a ...